New combo therapy shows promise against tough head and neck cancers
NCT ID NCT00304278
First seen Jun 08, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study tested a combination of the targeted drug Tarceva (erlotinib) and a special chemoradiation treatment called RADPLAT in 21 patients with advanced head and neck cancer. The goal was to see if the combination was safe and effective at shrinking tumors. Results measured how many patients had a complete or partial response, and how long they lived without the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Simmons Cooper Cancer Institute/SIU School of Medicine
Springfield, Illinois, 62702, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.